Ashley Gallagher, Editor

Data show significantly higher geometric mean titer ratios, meeting prespecified endpoints for superiority against the variant.

New study results show longer follow-up from phase ½ MajesTEC-1 study evaluating BCMAxCD3 bispecific antibody, including progression-free survival and subgroup analyses.

Individuals randomized to receive dabrafenib and trametinib had a statistically significant overall response rate of 47% compared with 11% for those who received chemotherapy.

The use of the treatment results in promising a response rate in patients with heavily pretreated RRMM, according to a presentation at the 2022 ASCO Annual Meeting.

Hispanic and individuals with lower incomes experienced sharper drops, reflecting emerging barriers and exacerbation of long-standing hurdles, analysis results indicate.

Glycosite-specific antibody‒drug conjugates (gsADCs), harnessing Asn297 N-glycan of IgG Fc as the conjugation site for drug payloads, usually require multi-step glycoengineering with 2 or more enzymes, which limits the substrate diversification and complicates the preparation process.

The topical therapy demonstrated significant improvements in the study, based on IGA success and other endpoints, according to investigators.

The treatment gives patients with neovascular age-related macular degeneration a more affordable option, the companies say.

The study has met its primary endpoint, with approximately 78.4% of women who continued taking the drug achieving the sustained responder rate through week 76.

The drug is being evaluated as the first potential allogeneic advanced cell therapy donor source for patients with blood cancers in need of a transplant.

The treatment also significantly reduces the risk of progression or death and prolonged median PFS compared with fulvestrant in all individuals without prior chemotherapy, the analysis shows.

This trend has been going on since before the start of the COVID-19 pandemic and is the cause of both in-person and telehealth visits, Epic Research said in a statement.

Approximately one-third of parents said their children are picky, and another third said they don’t think their children eat enough fruits and vegetables.

Investigators report that the 2 individuals receiving the 120-mg dosage had 3 probable immune-related adverse events, which provides supportive evidence of immune activation.

The new recommendations include 10 key points for managing this type of stroke, including training for home caregivers to improve patients’ quality of life.

The American Society of Health-System Pharmacists’ conference includes educational opportunities that feature the latest products, services, and technology in the industry.

Investigators reported that individuals who completed 10 cycles of lurbinectedin and doxorubicin who then switched to lurbinectedin as a monotherapy tended to have maintained or improved tumor response.

Investigators found that individuals receiving selinexor had a median PFS of 5.7 months compared to 3.8 months for those given the placebo, with a stratification adjusted hazard ratio of 0.70.

Investigators analyze the results of 71 clinical trials from around the world that were published between 1987 and 2020.

All individuals who received second-line chemotherapy regimens met the PFS2 endpoint and all but 1 individual had died at time of data cutoff, according to a presentation at 2022 ASCO Annual Meeting.

Rucaparib at the 400 mg dosage combined with nivolumab and ipilimumab for 4 cycles will continue onto a phase 2 trial for individuals with relapsed ovarian cancer.

Analysis included a 29% objective response rate in cohort 4 of the C-144-01 study, the company says.

Findings of the phase 2 cohort and the phase 1b cohort of the KRYSTAL-1 study are being presented at the 2022 American Society of Clinical Oncology Annual Meeting.

Efanesoctocog alfa is a novel and investigational recombinant factor VIII therapy that is designed to extend protection from bleeding with a once-weekly prophylactic dosing.

With a median follow-up of 90 months, individuals receiving palbociclib in combination with letrozole had numerically longer OS compared to placebo, but it was not deemed statistically significant.

Overall outcomes were consistent with axicabtagene ciloleucel in the real-world setting, regardless of race or ethnicity, in adults with relapsed or refractory large B-cell lymphoma.

Ibrutinib plus bendamustine-rituximab and rituximab maintenance was found to lower the risk of disease progression or death by 25% compared with placebo in patients 65 years of age or older with newly diagnosed mantle cell lymphoma.

Dupilumab is under clinical development, and the efficacy and safety have not been fully evaluated by any regulatory authorities.

The drug is a treatment for individuals who are healing all grades of erosive esophagitis, as a relief of heartburn, and as maintenance of healing all grades of EE and relief of heartburn.

Analysis shows that different genetic mutation profiles in tumors harboring PIK3CA mutation did not affect the treatment benefit with alpelisib (Piqray) combined with fulvestrant in individuals with HR+/HER2- advanced or metastatic breast cancer.